1,608 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC acquired a new stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,608 shares of the company’s stock, valued at approximately $548,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Primecap Management Co. CA acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $1,231,720,000. Temasek Holdings Private Ltd acquired a new stake in BeOne Medicines during the 2nd quarter valued at $244,603,000. Marshall Wace LLP acquired a new stake in BeOne Medicines during the 2nd quarter valued at $113,190,000. Baird Financial Group Inc. purchased a new position in BeOne Medicines during the second quarter worth $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of BeOne Medicines in the second quarter worth $73,347,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Stock Up 5.5%

Shares of ONC opened at $337.89 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $174.74 and a fifty-two week high of $385.22. The company’s fifty day moving average is $327.96 and its two-hundred day moving average is $313.24. The firm has a market cap of $37.05 billion, a PE ratio of 662.53 and a beta of 0.47. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03.

Analysts Set New Price Targets

A number of research firms recently commented on ONC. Royal Bank Of Canada reiterated an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th. Citizens Jmp boosted their price objective on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Barclays started coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective on the stock. Citigroup lifted their target price on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Morgan Stanley reissued an “overweight” rating and set a $405.00 price target on shares of BeOne Medicines in a research note on Thursday. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $367.36.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 75,631 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $307.79, for a total transaction of $23,278,465.49. Following the completion of the sale, the chief executive officer directly owned 24,369 shares in the company, valued at $7,500,534.51. This represents a 75.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Chan Henry Lee sold 996 shares of BeOne Medicines stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $349.17, for a total value of $347,773.32. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 128,610 shares of company stock worth $41,114,068 over the last ninety days. 6.62% of the stock is owned by insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.